Search results “Preclinical testing of viagra”
Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
PETACH TIKVA, Israel, Jan. 27, 2015 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported it has received positive data regarding its CF602 drug candidate in preclinical studies conducted by a third party. CF602 was tested in an experimental animal model of diabetic rats, which similar to diabetic patients, suffer from sexual dysfunction. Erectile dysfunction was assessed by monitoring the ratio between intra-cavernosal pressure (ICP) and mean arterial pressure (MAP) as a physiological index of erectile function. The ICP/MAP for the CF602 treated group improved by 118% over the placebo group. This data is similar to that achieved earlier by sildenafil (Viagra) in preclinical studies. In addition, treatment with CF602 reversed smooth muscle and endothelial damage, in a dose dependent manner, leading to the improvement in erectile dysfunction. CF602 is a novel A3 adenosine receptor allosteric modulator, enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor. "Our drugs, based on the A3 adenosine receptor platform, have been administered to over 1,200 patients in clinical studies and shown an excellent safety profile. We believe this has the potential to give us a huge advantage over current drugs in the erectile dysfunction market which are known to have adverse effects, hampering diabetic patients and other populations from using them on a daily basis," stated Can-Fite CEO Dr. Pnina Fishman. Based on positive results from this preclinical study, the Company recently announced its plans to initiate a pre-clinical development program for CF602 in order to file an investigational new drug application (IND) with the U.S. Food and Drug Administration to allow human Phase I studies for the indication of sexual dysfunction. Can-Fite has a strong intellectual property position which includes an issued "composition of matter" patent and other pending patent applications protecting the use for sexual dysfunction. GlobalData estimates the value of the erectile dysfunction therapeutic market to be approximately $2.7 billion with few drugs in the market which include Viagra, Cialis and Levitra.
Views: 170 CorporateProfile
Dr. Larry Cahill: Challenging Assumptions About Sex in Preclinical Research
Dr. Larry Cahill, Professor, Neurobiology and Behavior at the University of California, Irvine, talks to the NIH Office of Research on Women’s Health in regard to challenging assumptions about sex in preclinical research.
Views: 829 NIHOD
Sex and the Science of Testing Meds: You Don’t Know the Half of It
In 2013, the Food and Drug Administration cut the dosage for the sleep aid Ambien in half for women because it left them drowsy in the morning and more at risk for accidents. That was 21 years after the drug was approved for sale. “Here we see a troubling but thankfully well-publicized example of what happens when women are not fully considered in medical research,” said Dr. Carolyn M. Mazure, Director of Women’s Health Research at Yale. “We should not have to wait for women to begin reporting drug-induced car accidents before they are prescribed medication in the proper doses.” According to the Centers for Disease Control, about 4 percent of adults in the United States surveyed between 2005 and 2010 used prescription sleep aids sometime in the previous month, including 5 percent of adult women. The FDA has reported the results of driving simulation and laboratory studies showing that after eight hours of taking the pre-2013 recommended dosage for immediate-release Ambien (zolpidem) and equivalent drugs, 15 percent of women and 3 percent of men had concentrations in their blood that could impair driving. For the previous dosage recommendation of extended-release Ambien, 33 percent of women and 25 percent of men had potentially dangerous blood concentrations. Even at half of the extended-release dosage (the current recommendation), 15 percent of adult women and 5 percent of adult men had blood levels high enough to endanger their driving. For men, the agency only recommended that health care providers “consider” prescribing the lower doses recommended for women. Subsequent research has shown that even after controlling for weight, quantitative measures of reduced perceptual processing and reaction time were worse for women than men. “Researchers consider many variables when designing experiments and analyzing their results,” Mazure said. “What happened with Ambien demonstrates the necessity to include sex and gender as one of those variables.” And it’s not just Ambien. From 1997-2000, eight of the 10 drugs taken off the market posed a more serious risk to women than men. In a study to determine the serious fainting risk of drinking alcohol while taking the newly approved female libido pill, Addyi, 23 out of the 25 people tested were men. That’s just two women studied for a drug intended only for women. Last year, the FDA announced an action plan to improve the inclusion of women and the reporting of subgroup data in clinical studies. Last month, the National Institutes of Health began implementing a new policy calling for grant recipients to use and report results for both male and female animals in preclinical studies unless they provide strong justification for studying only one sex. In addition, because every human and animal cell has a sex, the NIH will encourage researchers to consider and report on the sex of cells as a biological variable. But the NIH policy does not require that researchers include adequate numbers of subjects of both sexes to ensure that they can draw statistically significant conclusions about the possible effect of sex on their experimental observations. Mazure praised these steps as important, if incomplete. “If health researchers know anything, it’s that they will never know what they don’t investigate,” Mazure said. “We need researchers to study and analyze their data by gender. To protect everybody.”
LMD & Genetic Analyses in new Preclinical Models -  Elisa Giovannetti
In this Webinar, after a technical presentation by Dr. Tamara Straube, Dr. Giovannetti discuss the advantages of using LMD techniques for precise, contamination-free isolation of specific cell types in various applications, such as using pancreatic cancer tissue sections from patients and orthotopic xenografts. Thus, this webinar provides an overview of the scientific and practical considerations for obtaining highly pure material for molecular analysis in the field of pharmacological studies to overcome key mechanisms of resistance in pancreatic cancer.
30. Esomeprazole as an Example of Drug Testing and Usage
Freshman Organic Chemistry (CHEM 125) The chemical mode of action of omeprazole is expected to be insensitive to its stereochemistry, making clinical trials of the proposed virtues of a chiral switch crucial. Design of the clinical trials is discussed in the context of marketing. Otolaryngologist Dr. Dianne Duffey provides a clinician's perspective on the testing and marketing of pharmaceuticals, on the FDA approval process, on clinical trial system, on off-label uses, and on individual and institutional responsibility for evaluating pharmaceuticals. 00:00 - Chapter 1. Introduction: The Chemical Properties and Reactivity of Prilosec 06:58 - Chapter 2. The Economics of Clinical Trials 19:57 - Chapter 3. Duffey: How Do I Know that the Drug is Effective? 30:26 - Chapter 4. The Phases of Clinical Trials, Results for Esomeprazole and Omeprazole, and Off-Label Use 42:01 - Chapter 5. Pharmaceutical Marketing Mentality and Q&A Complete course materials are available at the Open Yale Courses website: http://open.yale.edu/courses This course was recorded in Fall 2008.
Views: 8439 YaleCourses
Harmone - Injections Of This New Hormone May Make You Horny Again | injecting testosterone
Harmone - Injections Of This New Hormone May Make You Horny Again | injecting testosterone Injections Of This New Hormone May Make You Horny Again Boost Your Libido: Good news for guys struggling with low sex drive: Injections of a hormone called kisspeptin may jumpstart your lagging libido, scientists from the U.K. say. The researchers discovered that injecting the newly-discovered, naturally-occurring hormone stimulated areas of the brain typically activated by sexual arousal and romance. Research is still preliminary, but it’s possible the findings may one day be used to treat men with psychological sexual problems - commonly occurring in those struggling with infertility. Praise Poop: Fecal transplants - where stool from a healthy donor is transferred to a sick patient - have been used to treat severe, recurring diarrhea that results as a complication of antibiotic therapy. Now, it may have another use: A small study from the Ohio State University found that children with autism who received fecal transplants experienced an improvement in autism-related symptoms and gastrointestinal symptoms. Larger, more rigorous studies must be done to confirm the results before it can be used clinically, the researchers say. Sleep Well: Think your sleep sucks? It might, especially if you’re not hitting the determinants of quality sleep, as established by a panel of sleep experts. The key factors related to good sleep are: sleeping more than 85 per cent of the time you’re in bed, falling asleep within 30 minutes or less, waking up no more than once per night, and awakening for 20 minutes or less after initially falling asleep, according to the National Sleep Foundation. Reverse Memory Loss? Turn up the radio: Music may help reverse early memory loss, according to a new study in the Journal of Alzheimer’s Disease. After adults with subjective cognitive decline - a possible preclinical sign of Alzheimer’s - completed either a beginner meditation or music-listening program for 12 minutes a day for 12 weeks, they showed significant improvements in memory function.
Views: 2120 Care Tv
Riociguat is a novel drug that is a stimulator of soluble guanylate cyclase. Clinical trials have looked at riociguat as a new approach to treat two forms of pulmonary hypertension: chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Riociguat constitutes the first drug of a novel class of sGC stimulators. This video is targeted to blind users. Attribution: Article text available under CC-BY-SA Creative Commons image source in video
Views: 2497 Audiopedia
Pharmaceutical Drugs That Changed Our World
Pharmaceutical Drugs That Changed Our World Pharmaceutical Drugs That Changed Our World Viagra Aspirin Penicillin You liked the music that played in this video? The Tadros Brother are also a performing duo and have 8 albums but also love doing 3 Info-entertainment videos a day. Discover them here: https://itunes.apple.com/ca/artist/tadros-brothers/id680352095 https://itunes.apple.com/ca/artist/tadros/id399429 Rebel: http://youtu.be/wuvLqRIFD0E C'est ainsi: http://youtu.be/VMuMIocXvzU Pornstar: http://youtu.be/_IIPtUgwD5g Yo quiero Bailar: http://youtu.be/FkVWbxIpmq0 Music By Tadros Brothers: Buy https://itunes.apple.com/ca/album/djembe/id1105075833 https://itunes.apple.com/ca/artist/les-freres-tadros/id1104075284 Facebook: https://www.facebook.com/TadrosBrothers/ Twitter: https://twitter.com/tadros_brothers Original Djembe Video: https://www.youtube.com/watch?v=wHpHrdG3VN0
Introduction to Clinical Pharmacology and Therapeutics - Module 1, Session 1
Introduction to Clinical Pharmacology and Therapeutics - Module 1, Session 1 with Dr. Juan J. L. Lertora This is Module 1, Session 1, of the NIH Clinical Center's "2017-2018 Principles of Clinical Pharmacology" course. The course is a lecture series covering the fundamentals of clinical pharmacology as a translational scientific discipline focused on rational drug development and utilization in therapeutics. If you have any questions or need additional information regarding the Principles of Clinical Pharmacology course, please email the course coordinator at: cc-od_clinp@mail.nih.gov.
Views: 6409 NIH Clinical Center
Methods and Techniques for Integrating the Biological Variable "Sex" in Preclinical Research - AM
Methods and Techniques for Integrating the Biological Variable "Sex" in Preclinical Research - Morning Session Air date: Monday, October 20, 2014, 7:45:00 AM Category: Conferences Description: Office of Research on Women's Health The “Methods and Techniques for Integrating the Biological Variable Sex in Preclinical Research” workshop sponsored by the Office of Research on Women’s Health will focus on the incorporation of sex in basic science research studies. Session Topics will include: The rational for including male and female subjects in studies; the impact of including or not including sex as a basic biological variable; practical methods to integrate the biological variable “sex” into research projects; and how to cultivate a culture of “Sex Matters” across multiple disciplines. The workshop will include presentations from Dr. Lawrence Tabak, Deputy Director, NIH and Dr. Lawrence Cahill, Professor, University of California, Irvine. For more information go to http://orwh.od.nih.gov Author: Office of Research on Women's Health, NIH Permanent link: http://videocast.nih.gov/launch.asp?18686
Views: 935 nihvcast
Purple Transformer Piperazine
Purple Transformer Piperazine
Views: 33 Wilma Wiggins
TRACO 2016: Radiation oncology and Small molecules
TRACO 2016: Radiation oncology and Small molecules Air date: Wednesday, October 12, 2016, 4:00:00 PM Category: TRACO Runtime: 01:49:40 Description: Radiation oncology and Small molecules For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: E. Nichols, MD., University of Maryland and Anton Simeonov, Ph.D.,NIH Permanent link: https://videocast.nih.gov/launch.asp?19919
Views: 461 nihvcast
TRACO 2016: Genomics and Case reports
TRACO 2016: Genomics and Case reports Air date: Monday, October 31, 2016, 4:00:00 PM Category: TRACO Runtime: 01:43:41 Description: Genomics and Case reports For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: Jun S. Wei, Ph.D, NCI, NIH and Oluwadamilola Olaku, MD, NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?19975
Views: 268 nihvcast
Potential Benefits of Herbal and Dietary Supplements
Presented by Stanford Cancer Supportive Care Program Cancer patients are often interested in using herbal and dietary supplements as forms of alternative medicine. This presentation gives a brief overview, answers some common questions, and discusses the appropriate use of herbal and dietary supplements. Speakers: Abraham Chang, PharmD and Eun Jeong Kim, PharmD, MS
PCSBI Meeting Two: Sept. 13-14, 2010 in Philadelphia, Penn., Session 3: Knowledge Sharing,
Recordings of the public meetings of the Presidential Commission for the Study of Bioethical Issues (2009 - 2017). 10:45 a.m.-12 p.m. Session 3: Knowledge Sharing, Innovation and Translating Research for the Public Good [Video] [Transcript] Arti K. Rai, J.D. Elvin R. Latty Professor of Law Duke University School of Law Center for Public Genomics, Institute for Genome Sciences and Policy Duke University Ashley J. Stevens, D.Phil. [Slides] Special Assistant to the Vice President of Research Office of Technology Development Senior Research Associate, Institute for Technology Entrepreneurship and Commercialization Boston University President, Association of University Technology Managers David B. Weiner, Ph.D. [Slides] Professor, Pathology Laboratory Medicine Chair, Therapy and Vaccines Program CAMB University of Pennsylvania
Views: 14 Bioethics Library
PACCARB Day 1 Presentation: Incentives - International Experience
Third public meeting of the Presidential Advisory Council on Combating Antibiotic Resistant-Bacteria (PACCARB). For more information, visit http://www.hhs.gov/ash/advisory-committees/paccarb. -- U.S. Department of Health and Human Services (HHS) http://www.hhs.gov We accept comments in the spirit of our comment policy: http://www.hhs.gov/web/socialmedia/policies HHS Privacy Policy http://www.hhs.gov/Privacy.html